Marinomed Biotech AG provides Solv4U technology partnerships which address solubility and bioavailability issues and supports formulation development of both well-established API’s and new chemical entities (NCE’s), in all stages of drug development, based on its proprietary innovative Marinosolv® technology platform.
Our formulation development specialists provide you the optimal dosage form for your API and application, based on our Marinosolv® technology. Through this Marinosolv® technology we address solubility and bioavailability issues of hardly soluble small molecules and to support formulation development of Active Pharmaceutical Ingredients in all stages of drug development.
Our analytical specialists develop methods for quantification of your API in the developed formulation, based on the current guidelines. Furthermore, we can support the formulation development with analysis of impurities in stability studies as well as the preclinical development to evaulate the bioavailability of the API in several target tissues.
We support you to transfer the novel formulation, analytical method and all necessary preclinical data from our lab to your facility of choice, either your own manufacturing unit or any chosen C(D)MO. Our team assists you through every step of scale up, identification of critical process parameters, as well as troubleshooting. Furthermore, we provide you all collected data necessary for your documentatoin of pharmaceutical development.
